Name of the issue: Yatharth Hospital & Trauma Care Services Limited

1	Type of issue (IPO/ FPO)	Initial Public Offer
2	Issue size (Rs. million) * Source: Prospectus	6,865.51*
3	Grade of issue alongwith name of the rating agency Name Grade	Not Applicable
4	Subscription level (number of times) * *The above figure is including Anchor Portion and before technical rejections.	26.42 times*
	Source: Basis of Allotment advertisement dated August 5, 2023	

5 QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges

Date	%
August 02, 2023	13.33%
September 30, 2023	14.49%
March 31, 2024	13.32%
March 31, 2025	Not Available
March 31, 2026	Not Available
	August 02, 2023 September 30, 2023 March 31, 2024 March 31, 2025

(1) Source :Reporting with the BSE. Represents holding of Institutions category

⁽²⁾ Will be updated in due course

6 Consolidated Financials of the issuer

			(Rs. in Million)
Parameters	1st FY (FY 2023-24)	2nd FY (FY 2024-25)*	3rd FY (FY 2025-26)*
Income from operations	6705.47	Not Available	Not Available
Net Profit for the period	1145.87	Not Available	Not Available
Paid-up equity share capital	858.50	Not Available	Not Available
Reserves excluding revaluation reserves	7884.73	Not Available	Not Available

* Financials for the year ended March 31, 2025 and March 31, 2026 shall be updated in due course

7 Trading status in the scrip of the issuer

Company's Equity Shares are listed on both the BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2025)*	Not Available
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available

* Trading status not disclosed as the relevant fiscal years have not been completed

8 Change, if any, in directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed/ Resigned
(i) During year ended (March 31, 2024)	Not Applicable	Not Applicable
(ii) During year ended (March 31, 2025)*	Not Available	Not Available
(iii) During year ended (March 31, 2026)*	Not Available	Not Available

Source: Stock Exchange Filings

*Changes in Directors not disclosed as the relevant fiscal year has not been completed.



9 Status of implementation of project/ commencement of commercial production

Particulars	Remarks
(i) as disclosed in the offer document	Not Available
(ii) Actual implementation	Not Available
(iii) Reasons for delay in implementation, if any	Not Available

10 Status of utilization of issue proceeds

Doutionland	Duan aged Utilisitation	(in ₹ million)	
Particulars	Proposed Utilisitation	Fiscal 2024	Fiscal 2025
(i) as disclosed in the offer document			
Repayment/ prepayment, in full or part, of certain borrowings availed of by our Company	1,000.00	1,000.00	-
Repayment/ prepayment, in full or part, of certain borrowings availed of by our Subsidiaries, namely, AKS and Ramraja	1,450.00	1,450.00	_
Funding capital expenditure expenses of our Company for two hospitals, namely, Noida Hospital and Greater Noida Hospital	256.44	256.44	-
Funding capital expenditure expenses of our Subsidiaries, AKS and Ramraja, for respective hospital operated by them	1,069.66		1,069.66
Funding inorganic growth initiatives through acquisition and other strategic initiatives	650.00		nancial Years from the date of e Equity Shares.
General corporate purposes	1,271.00	1,271.00	-
Total	5,697.10	5,047.10	-
(ii) Actual utilization			
Repayment/ prepayment, in full or part, of certain borrowings availed of by our Company	1,000.00	1,000.00	Not Available
Repayment/ prepayment, in full or part, of certain borrowings availed of by our Subsidiaries, namely, AKS and Ramraja	1,450.00	1,427.20	Not Available
Funding capital expenditure expenses of our Company for two hospitals, namely, Noida Hospital and Greater Noida Hospital	256.44	179.90	Not Available
Funding capital expenditure expenses of our Subsidiaries, AKS and Ramraja, for respective hospital operated by them	1,069.66	300.90	Not Available
Funding inorganic growth initiatives through acquisition and other strategic initiatives	650.00	-	Not Available
General corporate purposes	1,271.00	419.80	Not Available
Total	5,697.10	3,327.80	Not Available
(iii) Reasons for deviation, if any			
Not Available			

11 Comments of monitoring agency, if applicable

(a) Comments on use of funds	Not Available
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	Not Available
(c) Any other reservations expressed by the monitoring agency about the end use of funds	Not Available

12 Price- related data

I Ince- I chatcu data						
Designated Stock Exchange:	BSE Limite	d				
Issue price (Rs):	Rs. 300/- per shar	e				
Listing Date:	August 07, 202	3				
		At close of 30th calendar	· At close of 90th calendar day	As at the end of 1st FY after the listing of the Issue (March 31, 2024)		
Price parameters	At close of listing day - (August 07, 2023) day fr	day from listing day- (September 5, 2023)	from listing day-	Closing price during the FY	High during the FY	Low during the FY
Market Price	333.75	369.90	361.75	417.30	488.80	311.70
BSE Sensex*	65,953.48	65,880.52	64,958.69	73,651.35	74,245.17	58,793.08
Duise novemeters	As at the end of 2nd FY aft	As at the end of 2nd FY after the listing of the Issue (March 31, 2025) ⁽¹⁾		As at the end of 3rd FY after the listing of the Issue (March 31, 2026) ⁽¹⁾		
Price parameters	Closing price during the FY	High during the FY	Low during the FY	Closing price during the FY	High during the FY	Low during the FY
Market Price	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
BSE Sensex*	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Source: BSE website	·	÷	÷			

* Being index of BSE, the designated stock exchange

⁽¹⁾ The pricing data is not disclosed as the relevant fiscal years have not been completed

Accounting ratio	Name of company	As disclosed in the offer document*	At the end of 1st FY (March 31, 2024)*	At the end of 2nd FY (March 31, 2025)**	At the end of 3rd I (March 31, 2026) ³
	Issuer				
	Consolidated (Basic)	10.09	13.33	Not Available	Not Available
	Consolidated (Diluted)	10.09	13.33	Not Available	Not Available
	Peer Group (Consolidated)				
	Apollo Hospitals Enterprise Limited	56.97	Not Available	Not Available	Not Available
EPS	Fortis Healthcare Limited	7.80	7.93	Not Available	Not Available
EF 5	Narayana Hrudalaya Limited	29.85	38.60	Not Available	Not Available
	Max Healthcare Institute Limited	11.38	10.90	Not Available	Not Available
	Krishna Institute of Medical Sciences		38.76	Not Available	Not Available
	Limited	42.03			
	Healthcare Global Enterprises Limited	2.11	Not Available	Not Available	Not Available
	Global Health Limited	12.58	17.81	Not Available	Not Available
	Issuer				
	Consolidated (Diluted)	5,202.93	6,705.47	Not Available	Not Available
	Peer Group (Consolidated)				
	Apollo Hospitals Enterprise Limited	1,66,124.50	1,90,592.00	Not Available	Not Available
	Fortis Healthcare Limited	62,976.32	68,929.20	Not Available	Not Available
Revenue from Operations (Rs. Million)	Narayana Hrudalaya Limited	45,247.65	50,182.49	Not Available	Not Available
	Max Healthcare Institute Limited	45,626.00	54,060.20	Not Available	Not Available
	Krishna Institute of Medical Sciences			Not Available	Not Available
	Limited	21,976.78	24,981.44		
	Healthcare Global Enterprises Limited	16,914.10	19,078.70	Not Available	Not Available
	Global Health Limited	26,942.48	32,751.11	Not Available	Not Available
	Issuer				
	Consolidated (Diluted)	29.73	31.60	Not Available	Not Available
	Peer Group (Consolidated)				
	Apollo Hospitals Enterprise Limited	89.44	Not Available	Not Available	Not Available
	Fortis Healthcare Limited	40.36	52.99	Not Available	Not Available
Price to Earnings Ratio (P/E)	Narayana Hrudalaya Limited	33.29	33.26	Not Available	Not Available
8 ()	Max Healthcare Institute Limited	52.66	75.22	Not Available	Not Available
	Krishna Institute of Medical Sciences		53.13	Not Available	Not Available
	Limited	42.44			
	Healthcare Global Enterprises Limited	151.02	Not Available	Not Available	Not Available
	Global Health Limited	52.44	74.22	Not Available	Not Available
	Issuer		,	1,00111,0110010	1.0011.0010
	Consolidated (Diluted)	35.95	21.57	Not Available	Not Available
	Peer Group (Consolidated)	55.75	21.07		
	Apollo Hospitals Enterprise Limited	13.22	Not Available	Not Available	Not Available
	Fortis Healthcare Limited	8.13	8.65	Not Available	Not Available
RoNW(%)	Narayana Hrudalaya Limited	28.44	31.47	Not Available	Not Available
	Max Healthcare Institute Limited	14.89	13.38	Not Available	Not Available
	Krishna Institute of Medical Sciences	14.07	19.21	Not Available	Not Available
	Limited	20.14	17.21	Not Available	Not Available
	Healthcare Global Enterprises Limited	3.41	Not Available	Not Available	Not Available
	Global Health Limited	13.43	17.92	Not Available	Not Available
	Issuer	15.45	17.72	Not Available	not Available
	Consolidated (Diluted)	27.93	101.84	Not Available	Not Available
	Peer Group (Consolidated)	21.93	101.04	Not Available	not Available
		89.44	Not Available	Not Available	Not Available
	Apollo Hospitals Enterprise Limited Fortis Healthcare Limited	40.36		Not Available	Not Available Not Available
NAV non E St		33.29	101.50		
NAV per Equity Share	Narayana Hrudalaya Limited		140.78	Not Available	Not Available
	Max Healthcare Institute Limited	52.66	86.52	Not Available	Not Available
	Krishna Institute of Medical Sciences	40.44	228.47	Not Available	Not Available
	Limited	42.44	NT / A 111	NT / 1 111	37.4 444
	Healthcare Global Enterprises Limited	151.02	Not Available	Not Available	Not Available
	Global Health Limited	52.44	108.21	Not Available	Not Available

* Sourced from Prospectus dated July 30, 2023

** Not available as the relevant fiscal years have not been completed / information not disclosed

Company informed stock exchanges that Search Operation was carried out by Income Tax Department at Company has acquired M/s. Ramraja Multispeciality Hospital & Trauma Centre Private Limited Acquisition of 100% equity shares in Pristine Infracon Private Limited

For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by Intensive Fiscal Services Private Limited ("Intensive") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and / or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by Intensive to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, Intensive does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither Intensive nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. Intensive does not undertake to update the information contained herein except as required by applicable law or regulation.

22-Oct-23 28-Nov-23 10-Feb-24